Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancers
Publication date: Available online 21 September 2020Source: Pathology - Research and PracticeAuthor(s): He Zhang, Yi Wang, Yanfeng Wang, Daoyuan Wu, Enguang Lin, Qingxin Xia
ConclusionThese results highlight the effectiveness of pyrotinib combined with apatinib in HER2-positive GC and acquired pyrotinib resistance, thus providing a theoretical basis for new treatment methods.
In this study, in silico analyses of the lysine histone demethylases (KDMs) involved in diverse biological processes and diseases revealed that PHD finger protein 8 (PHF8, KDM7B) was...
The importance of targeted therapy for gastric cancer (GC) has increased in recent years with anti-HER2 therapy and immunotherapy for microsatellite instability (MSI) and PD-L1+ tumors. However, most of the trials does not include remnant GC (RGC), so the potential for target therapy in these patients remains unknow. Our objetive was to evaluate the clinicopathological characteristics of RGC and its association with the expression of current markers for target therapy.
SummaryThe prognosis of patients with metastatic gastroesophageal cancer remains poor despite numerous promising clinical trials, and the clinical benefit of systemic therapies is under critical review. This case report of a patient with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma is an impulse for the importance of individual decision making and molecular guided treatment options.
ConclusionOur study confirms the effect of DPF is highly dependent on several clinical –pathological variables, with discreet and gradually declining benefit over platinum doublets in later years, at the expense of increased toxicity. These results may help to underpin the idea that external validity of AGC trials should be revised regularly.
Authors: Yan Y, Xu J, Mao G Abstract BACKGROUND The purpose of our study was to determine the effects and mechanisms of honokiol on human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells by in vitro study. MATERIAL AND METHODS We measured HER2 expression in different gastric cancer cell lines by real-time quantitative polymerase chain reaction (RT-qPCR) and western blot (WB) assay. Cell proliferation, apoptosis, and cell cycle were evaluated by cell-counting kit 8 and flow cytometry assays. The invading cell numbers and wound-healing rates were measured by transwell and wound-healing assays. ...
Condition: HER2-positive Gastric Cancer Intervention: Genetic: ctDNA screening Sponsor: Ruijin Hospital Recruiting
AbstractBackgroundCisplatin plus S-1 (CS) is the standard first-line chemotherapy for advanced gastric cancer (AGC) in Japan. A previous phase III trial showed that docetaxel plus S-1 (DS) was effective for AGC without measurable lesions, but no studies have compared these two regimens.MethodsEligible patients had unresectable or recurrent HER2-negative AGC without measurable lesions. Patients were randomized to DS (docetaxel 40 mg/m2 on day 1, S-1 80 –120 mg on days 1–14, every 3 weeks) or CS (cisplatin 60 mg/m2 on day 8, S-1 80 –120 mg on days 1–21, every 5 weeks). T...